Advertisement

Drug Safety

, Volume 15, Issue 5, pp 347–359 | Cite as

Corticosteroid-Induced Bone Loss

Prevention and Management
  • César Picado
  • Maite Luengo
Review Article Pharmacoepidemiology

Summary

Osteoporosis is one of the most serious adverse effects experienced by patients receiving long term corticosteroid therapy. Bone loss occurs soon after corticosteroid therapy is initiated and results from a complex mechanism involving osteoblastic suppression and increased bone resorption. There are a number of factors that may increase the risk of corticosteroid-induced osteoporosis [smoking, excessive alcohol (ethanol) consumption, amenorrhoea, relative immobilisation, chronic obstructive pulmonary disease, inflammatory bowel disease, hypogonadism in men, organ transplantation].

The initial assessment of patients about to start taking corticosteroids should include measurement of spinal bone density, urinary calcium level and plasma calcifediol (25-hydroxycholecalciferol) level; serum testosterone levels should also be measured when hypogonadism is suspected.

Many different drugs have been used to prevent osteoporosis in patients receiving long-term corticosteroid therapy, including thiazide diuretics, chole-calciferol (vitamin D) metabolites, bisphosphonates, calcitonin, fluoride, estrogens, anabolic steroids and progesterone. At present, however, published studies have failed to demonstrate a reduction in the rate of fracture using different preventive pharmacological therapies in patients being treated with corticosteroids on a continuous basis.

Among the drugs studied, bisphosphonates (pamidronic acid and etidronic acid) and calcitonin appear to be effective in increasing bone density. Cholecalciferol preparations have been reported to be effective in some, but not all, studies. Limited data have shown positive results with thiazide diuretics, estrogen, progesterone and nandrolone.

When treating patients with corticosteroids, the lowest effective dose should be used, with topical corticosteroids used whenever possible. Auranofin may be considered in patients with corticosteroid-dependent asthma. Patients should take as much physical activity as possible, maintain an adequate daily intake of calcium (1000 mg/day) and cholecalciferol (400 to 800 U/day), stop smoking and avoid excessive alcohol intake. It is important to detect and treat hypogonadism in men, if present, and to replace gonadal hormones in postmenopausal women or amenorrhoeic premenopausal women, and to detect and correct cholecalciferol deficiency. A thiazide diuretic should be considered if hypercalciuria is present (urinary calcium excretion in excess of 4 mg/kg/day).

High-risk patients and those with established osteoporosis should be treated with bisphosphonates (cyclical etidronic acid or intravenous pamidronic acid), nasal calcitonin, or calcifediol or calcitriol. Patients receiving cholecalciferol preparations should be carefully monitored for hypercalciuria and hypercalcaemia.

Keywords

Osteoporosis Allergy Clin Immunol Auranofin Salmon Calcitonin Urinary Calcium Excretion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Cushing H. The basophilic adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). Bull Johns Hopkins Hosp 1932; 1: 137–92Google Scholar
  2. 2.
    Soffer JL, Iannaccone A, Gabrilove JL. Cushing’s syndrome: a study of fifty patients. Am J Med 1961; 30: 129–46Google Scholar
  3. 3.
    Howland WJ, Pugh DG, Sprague RG. Roentgenologic changes of the skeletal system in Cushing’s syndrome. Radiology 1958; 71: 69–78PubMedGoogle Scholar
  4. 4.
    Adinoff AD, Hollister JR. Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med 1983; 309: 265–8PubMedGoogle Scholar
  5. 5.
    Michel BA, Bloch DA, Fries JF. Predictors of fractures in early rheumatoid arthritis. J Rheumatol 1991; 18: 804–8PubMedGoogle Scholar
  6. 6.
    Luengo M, Picado C, Piera C, et al. Intestinal calcium absorption and parathyroid hormone secretion in asthmatic patients on prolonged oral or inhaled steroid treatment. Eur Respir J 1991; 4: 441–4PubMedGoogle Scholar
  7. 7.
    Greenberger PA, Hendrix RW, Patterson R, et al. Bone studies in patients on prolonged systemic corticosteroid therapy for asthma. Clin Allergy 1982; 12: 363–8PubMedGoogle Scholar
  8. 8.
    Rees HA, Williams DA. Long-term therapy in chronic intractable asthma. BMJ 1962; I: 1575–9Google Scholar
  9. 9.
    Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 1990; 112: 352–64PubMedGoogle Scholar
  10. 10.
    Sambrook Ph, Birmingham J, Kempler S, et al. Corticosteroid effects on proximal femur bone loss. J Bone Miner Res 1990; 5: 1211–6PubMedGoogle Scholar
  11. 11.
    Reid IR, Heap SW. Determinants of vertebral mineral density in patients receiving chronic glucocorticoid therapy. Arch Intern Med 1990; 150: 2545–8PubMedGoogle Scholar
  12. 12.
    Suzuki Y, Ichikawa Y, Saito E, et al. Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients under glucocorticoid therapy. Metabolism 1983; 32: 151–6PubMedGoogle Scholar
  13. 13.
    Hahn TJ, Halstead LR, Baran DT. Effects of short-term glucocorticoid administration on intestinal calcium absorption and circulating vitamin D metabolite concentration in man. J Clin Endocrinol Metab 1981; 52: 111–5PubMedGoogle Scholar
  14. 14.
    Klein RG, Arnaud SB, Gallagher JC, et al. Intestinal calcium absorption in exogenous hypercortisolism: role of 25-hydroxyvitamin D concentrations in patients receiving chronic corticosteroid therapy. J Lab Clin Med 1971; 60: 253–9Google Scholar
  15. 15.
    Avioli LV, Birge SJ, Lee SW. Effect of prednisone on vitamin D metabolism in man. J Clin Endocrinol Metab 1968; 28: 1341–6PubMedGoogle Scholar
  16. 16.
    Chesney RW, Mazees RB, Hamstra AJ, et al. Reduction of serum 1,25-dyhydroxyvitamin-D in children receiving glucocorticoids. Lancet 1978; II: 1123–5Google Scholar
  17. 17.
    Zerwekh JE, Emkey RD, Harris ED. Low dose prednisone therapy in rheumatoid arthritis: effect on vitamin D metabolism. Arthritis Rheum 1984; 27: 1050–2PubMedGoogle Scholar
  18. 18.
    Hsueh AJ, Erickson GF. Glucocorticoid inhibition of FSH-induced estrogen production in cultured rat granulosa cells. Steroids 1978; 32: 639–48PubMedGoogle Scholar
  19. 19.
    Sakakura M, Takebe K, Nakagawa S. Inhibition of luteinizing hormone secretion by synthetic LRH by long-term treatment with glucocorticoids in human subjects. J Clin Endocrinol Metab 1975; 40: 774–9PubMedGoogle Scholar
  20. 20.
    McAdams MR, White RH, Chipps BE. Reduction of serum testosterone levels during chronic glucocorticoid therapy. Ann Intern Med 1986; 104: 648–51Google Scholar
  21. 21.
    Prummel MF, Wiersinga WM, Lips P, et al. The course of biochemical parameters of bone turnover during treatment with corticosteroids. J Clin Endocrinol Metab 1991; 72: 382–6PubMedGoogle Scholar
  22. 22.
    Dempster DW. Bone histomorphometry in glucocorticoid-induced 2 osteoporosis. J Bone Miner Res 1989; 4: 137–41PubMedGoogle Scholar
  23. 23.
    Ruegsegger P, Medici TC, Anliker M. Corticosteroid-induced bone loss: a longitudinal study of alternate day therapy in patients with bronchial asthma using quantitative computed tomography. Eur J Clin Pharmacol 1983; 25: 615–20PubMedGoogle Scholar
  24. 24.
    Gluck OS, Murphy WA, Hahn TJ, et al. Bone loss in adults receiving alternate day glucocorticoid therapy. Arthritis Rheum 1981; 24: 892–8PubMedGoogle Scholar
  25. 25.
    Lund V, Aaronson D, Bousquet J, et al. International consensus on the diagnosis and management of rhinitis. Allergy 1994; 49 Suppl.: 1–34Google Scholar
  26. 26.
    Guidelines on the management of asthma. Thorax 1993; 48 Suppl.: 1–24Google Scholar
  27. 27.
    Smith MJ, Hodson ME. Effects of long-term inhaled high dose beclomethasone dipropionate on adrenal function. Thorax 1983; 38: 676–81PubMedGoogle Scholar
  28. 28.
    Law CM, Marchant JL, Honour JW, et al. Nocturnal adrenal suppression in asthmatic children taking inhaled beclomethasone dipropionate. Lancet 1986; II: 942–4Google Scholar
  29. 29.
    Wyatt R, Wascheck MS, Weinberger S, et al. Effects of inhaled beclomethasone dipropionate and alternate day prednisolone on pituitary-adrenal function in children with chronic asthma. N Engl J Med 1978; 299: 1387–92PubMedGoogle Scholar
  30. 30.
    Reid DM, Nicoll JJ, Smith MA, et al. Corticosteroids and bone mass in asthma: comparisons with rheumatoid arthritis and polymyalgia rheumatica. BMJ 1986; 293: 1463–5PubMedGoogle Scholar
  31. 31.
    Packe GE, Douglas JG, McDonald AF, et al. Bone density in asthmatic patients taking high dose inhaled beclomethasone dipropionate and intermittent systemic corticosteroids. Thorax 1992; 47: 414–7PubMedGoogle Scholar
  32. 32.
    Ali NJ, Capewell S, Ward MJ. Bone turnover during high dose inhaled corticosteroid treatment. Thorax 1991; 46: 160–4PubMedGoogle Scholar
  33. 33.
    Pow EM, Prummel MF, Oosting H, et al. Beclomethasone inhalation decreases serum osteocalcin concentrations. BMJ 1991; 302: 627–6Google Scholar
  34. 34.
    Jenning B, Anderson K, Johansson S. Assessment of systemic effects of inhaled glucocorticosteroids: comparison of the effects of inhaled budesonide and oral prenisolone on adrenal function and markers of bone turnover. Eur J Clin Pharmacol 1991; 40: 77–82Google Scholar
  35. 35.
    Sorva R, Turpeinen M, Juntunen-Backman K, et al. Effects of inhaled budesonide on serum markers of bone metabolism in children with asthma. J Allergy Clin Immunol 1993; 122: 219–26Google Scholar
  36. 36.
    Kimberg KA, Hopp RJ, Biven RE, et al. Bone mineral density in normal and asthmatic children. J Allergy Clin Immunol 1994; 94: 490–7Google Scholar
  37. 37.
    Boulet LPH, Giguère MC, et al. Effects of long-term use of high-dose inhaled steroids on bone density and calcium metabolism. J Allergy Clin Immunol 1994; 94: 796–803PubMedGoogle Scholar
  38. 38.
    Baraldi E, Bollini MC, De Marchi A, et al. Effects of beclomethasone dipropionate on bone mineral content assessed by X-ray densitometry in asthmatic children: a longitudinal evaluation. Eur Respir J 1994; 7: 710–4PubMedGoogle Scholar
  39. 39.
    Kerstjens HAM, Postma DS, van Doormal JJ, et al. Effects of short term and long term treatment with inhaled corticosteroids on bone metabolism in patients with airways obstruction. Thorax 1994; 49: 652–6PubMedGoogle Scholar
  40. 40.
    Le Bourgeois M, Cormier C, Kindermans C, et al. Inhaled beclomethasone and bone metabolism in young asthmatic children: a six month study. J Allergy Clin Immunol 1995; 96: 565–7PubMedGoogle Scholar
  41. 41.
    Mullarkey MF, Webb DR, Pardee NE. Methotrexate in the treatment of steroid-dependent asthma. Ann Allergy 1986; 56: 347–50PubMedGoogle Scholar
  42. 42.
    Mullarkey MF, Blumenstein BA, Andrade WP, et al. Methotrexate in the treatment of corticosteroid-dependent asthma — a double blind cross-over study. N Engl J Med 1988; 318: 603–7PubMedGoogle Scholar
  43. 43.
    Shiner RJ, Nunn AJ, Chung KF, et al. Randomised, double-blind, placebo controlled trial of methotrexate in steroid-dependent asthma. Lancet 1990; 336: 137–40PubMedGoogle Scholar
  44. 44.
    Stewart GE, Diaz JD, Lockey RF, et al. Comparison of oral pulse methotrexate with placebo in the treatment of severe glucocorticosteroid-dependent asthma. J Allergy Clin Immunol 1994; 94: 482–9PubMedGoogle Scholar
  45. 45.
    Dyer PD, Vaughan TR, Weber RW. Methotrexate in the treatment of steroid-dependent asthma. J Allergy Clin Immunol 1991; 88: 208–12PubMedGoogle Scholar
  46. 46.
    Erzurum SC, Leff JA, Cochran JE, et al. Lack of benefit of methotrexate in severe, steroid-dependent asthma: a double-blind, placebo-controlled study. Ann Intern Med 1991; 114: 353–60PubMedGoogle Scholar
  47. 47.
    Coffey MJ, Sanders G, Eschenbacher WL, et al. The role of methotrexate in the management of steroid-dependent asthma. Chest 1994; 105: 117–21PubMedGoogle Scholar
  48. 48.
    Trigg CJ, Davies RJ. Comparison of methotrexate 30mg per week with placebo in chronic steroid-dependent asthma: a 12-week double-blind, cross-over study. Respir Med 1993; 87: 211–6PubMedGoogle Scholar
  49. 49.
    Alexander AG, Barnes NC, Kay AB. Trial of cyclosporin in corticosteroid-dependent chronic severe asthma. Lancet 1992; 339: 324–8PubMedGoogle Scholar
  50. 50.
    Lock SH, Barnes NC, Kay AB. Cyclosporin A (CsA) as a corticosteroid sparing agent in corticosteroid dependent asthma [abstract]. Thorax 1994; 49: 1051Google Scholar
  51. 51.
    Nizankowska E, Soja J, Pinis G. Treatment of steroid-dependent asthma with cyclosporin [abstract]. Am Rev Respir Dis 1993; 147 Suppl.: A294Google Scholar
  52. 52.
    Movsowitz C, Epstein S, Ismail F, et al. Cyclosporine A in vivo produces severe osteopenia in the rat: effect of dose and duration of administration. Endocrinology 1988; 123: 2571–8PubMedGoogle Scholar
  53. 53.
    Nierop G, Gijzel WP, Bel EH, et al. Auranofin in the treatment of steroid dependent asthma: a double blind study. Thorax 1992; 47: 349–54PubMedGoogle Scholar
  54. 54.
    Klauestermayer WB, Noritake DT, Kwong FK. Crysotherapy in the treatment of corticosteroid-dependent asthma. J Allergy Clin Immunol 1987; 79: 720–5Google Scholar
  55. 55.
    Barengolts EI, Curry DJ, Bapna MS, et al. Effects of endurance exercise on bone mass and mechanical properties in intact ovariectomized rats. J Bone Miner Res 1993; 8: 937–42PubMedGoogle Scholar
  56. 56.
    Yeh JK, Aloia JF, Chen MM, et al. Influence of exercise on cancellous bone of the aged female rat. J Bone Miner Res 1993; 8: 1117–25PubMedGoogle Scholar
  57. 57.
    Tommerup LJ, Raab DM, Crenshaw TD, et al. Does weight-bearing exercise affect non-weight-bearing-bone? J Bone Miner Res 1993; 8: 1053–8PubMedGoogle Scholar
  58. 58.
    Forwood MR, Burr DB. Physical activity and bone mass: exercise in futility?. Bone Miner 1993; 21: 89–112PubMedGoogle Scholar
  59. 59.
    Cavanaugh DJ, Cann CE. Brisk walking does not stop bone loss in postmenopausal women. Bone 1988; 9: 201–4PubMedGoogle Scholar
  60. 60.
    Välimäki M, Kärkkäinen M, Lamber-Allardt C, et al. Exercise, smoking and calcium intake during adolescence and early adulthood as determinants of peak bone mass. BMJ 1994; 309: 230–5PubMedGoogle Scholar
  61. 61.
    Hopper JL, Seeman E. The bone density of female twins discordant for tobacco use. N Engl J Med 1994; 330: 387–92PubMedGoogle Scholar
  62. 62.
    Peris P, Parés A, Guañabens N, et al. Bone mass improves in alcoholics after 2 years of abstinence. J Bone Miner Res 1994; 9: 1607–12PubMedGoogle Scholar
  63. 63.
    Nilsen KH, Jayson MIV, Dixon ASJ, et al. Microcrystalline calcium hydroxyapatite compound in corticosteroid-treated rheumatoid patients: a controlled study. BMJ 1978; II: 1124Google Scholar
  64. 64.
    Reid IR, Ibbertson HK. Calcium supplements in the prevention of steroid-induced osteoporosis. Am J Clin Nutr 1978; 44: 287–90Google Scholar
  65. 65.
    Luengo M, Picado C, del Rio L, et al. Treatment of steroid-induced osteopenia with calcitonin in corticosteroid-dependent asthma. Am Rev Respir Dis 1990; 142: 104–7PubMedGoogle Scholar
  66. 66.
    Luengo M, Pons F, Martinez de Osaba MJ, et al. Prevention of further bone mass loss by nasal calcitonin in patients on long term glucocorticoid therapy for asthma: a two year follow-up study. Thorax 1994; 49: 1099–102PubMedGoogle Scholar
  67. 67.
    Reid IR, Alexander CJ, King AR, et al. Prevention of steroid-induced osteoporosis with (3-amino-l-hydroxypropylidene)-1,1-bisphosphonate (APD). Lancet 1988; I: 143–6Google Scholar
  68. 68.
    Sambrook P, Birmingham J, Kelly P, et al. Prevention of corticosteroid osteoporosis — a comparison of calcium, calcitriol, and calcitonin. N Engl J Med 1993; 328: 1747–52PubMedGoogle Scholar
  69. 69.
    Worth H, Stammen D, Keck E. Therapy of steroid-induced bone loss in adult asthmatics with calcium, vitamin D and diphosphonate. Am J Respir Crit Care Med 1994; 150: 394–7PubMedGoogle Scholar
  70. 70.
    Berger-Lux MJ, Heaney RP. Caffeine and the calcium economy revisited. Osteoporos Int 1995; 5: 97–102Google Scholar
  71. 71.
    Adams JS, Wahl TO, Lukert BP. Effects of hydroxyclorothiaz ide and dietary sodium restriction on calcium metabolism in corticosteroid treated patients. Metabolism 1981; 30: 217–21PubMedGoogle Scholar
  72. 72.
    Suzuki Y, Ichikawa Y, Saito E, et al. Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients under glucocorticoid therapy. Metabolism 1983; 32: 151–6PubMedGoogle Scholar
  73. 73.
    Yamada H. Long-term effect of 1 alpha-hydroxyvitamin D, calcium and thiazide administration on glucocorticoid-induced osteoporosis. Nippon Naibunpi Gakkai Zasshi 1989; 65: 603–14PubMedGoogle Scholar
  74. 74.
    Wasnich R, Benfante J, Yano K, et al. Thiazide effect on the bone mineral content of bone. N Engl J Med 1983; 309: 344–7PubMedGoogle Scholar
  75. 75.
    Dykman TR, Haralson KM, Gluck OS, et al. Effect of oral 1,25-dihydroxyvitamin D and calcium on glucocorticoid-induced osteopenia in patients with rheumatic diseases. Arthritis Rheum 1984; 27: 1336–43PubMedGoogle Scholar
  76. 76.
    Gallagher JA, Aaron J, Horsman A, et al. Corticosteroid osteoporosis. Clin Endocrinol Metab 1973; 2: 355–68PubMedGoogle Scholar
  77. 77.
    Hahn TJ, Halstead LR, Teitelbaum ST, et al. Altered mineral metabolism in glucocorticoid-induced osteopenia: effect of 25-hydroxyvitamin D administration. J Clin Invest 1979; 64: 655–65PubMedGoogle Scholar
  78. 78.
    DiMunno O, Beghe F, Favini P, et al. Prevention of glucocorticoid osteopenia: effect of oral 25-hydroxyvitamin D and calcium. Clin Rheumatol 1989; 8: 202–7Google Scholar
  79. 79.
    Bijlsma JWJ, Raymakers JA, Mosch C, et al. Effects of oral calcium and vitamin D on glucocorticoid induced osteopenia. Clin Exp Rheumatol 1988; 6: 113–9PubMedGoogle Scholar
  80. 80.
    Rickers H, Deding A, Christiansen C, et al. Corticosteroid-in-duced osteopenia and vitamin D metabolism: effect of vitamin D2, calcium phosphate and sodium fluoride administration. Clin Endocrinol 1982; 16: 409–15Google Scholar
  81. 81.
    Braun JJ, Birkenhager-Frenkel DH, Rietveld JR, et al. Influence of lα-(OH)D3 administration on bone and bone mineral metabolism in patients on chronic glucocorticoid treatment: a double blind controlled study. Clin Endocrinol 1983; 19: 265–73Google Scholar
  82. 82.
    Meys E, Terreaux-Duvert F, Beaume-Six T, et al. Bone loss after cardiac transplantation: effects of calcium, calcidiol, and monofluorophosphate. Osteoporos Int 1993; 3: 322–9PubMedGoogle Scholar
  83. 83.
    Copp DH. Calcitonin: discovery, development, and clinical applications. Clin Invest Med 1994; 17: 268–77PubMedGoogle Scholar
  84. 84.
    Montemurro L, Schiraldi G, Fraioli P, et al. Prevention of corticosteroid-induced osteoporosis with salmon calcitonin in sarcoid patients. Calcif Tissue Int 1991; 49: 71–6PubMedGoogle Scholar
  85. 85.
    Rizzato G, Tosi G, Schiraldi G, et al. Bone protection and salmon calcitonin (sCT) in the long-term steroid therapy of chronic sarcoidosis. Sarcoidosis 1988; 5: 99–103PubMedGoogle Scholar
  86. 86.
    Ringe JD, Welzel D. Salmon calcitonin in the therapy of corticoid-induced osteoporosis. Eur J Clin Pharmacol 1987; 33: 35–9PubMedGoogle Scholar
  87. 87.
    Nishioka T, Kurayama H, Yasuda T, et al. Nasal administration of salmon calcitonin for prevention of glucocorticoid-induced osteoporosis in children with nephrosis. J Pediatr 1991; 118: 703–7PubMedGoogle Scholar
  88. 88.
    Devogelaer JP, Azria M, Attinger M, et al. Comparison of the acute biological action of injectable salmon calcitonin and an injectable and oral analogue. Calcif Tissue Int 1994; 55: 71–3PubMedGoogle Scholar
  89. 89.
    Overgaard K. Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: a dose-response study. Calcif Tissue Int 1994; 55: 82–6PubMedGoogle Scholar
  90. 90.
    Smith R, Russell RGG, Bishop M. Diphosphonates and Paget’s disease of bone. Lancet 1971: I: 945–7Google Scholar
  91. 91.
    Ralston SH, Gardner MD, Dryburgh FJ, et al. Comparison of aminohydroxypropylidene diphosphonate, mithramycin and corticosteroids/calcitonin in treatment of cancer-associated hypercalcaemia. Lancet 1985; II: 907–10Google Scholar
  92. 92.
    Storm T, Thamsburg G, Stenicke T, et al. Effect of intermittent cyclical etidronate therapy on bone mass in women with postmenopausal osteoporosis. N Engl J Med 1990; 322: 1265–71PubMedGoogle Scholar
  93. 93.
    Liberman UA, Weiss ST, Bröll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995; 333: 1437–43PubMedGoogle Scholar
  94. 94.
    Mulder H, Struys A. Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss. Br J Rheumatol 1994; 33: 348–50PubMedGoogle Scholar
  95. 95.
    Adachi JD, Cranney A, Goldsmith CH, et al. Intermittent cyclic therapy with etidronate in the prevention of corticosteroid-induced bone loss. J Rheumatol 1994; 21: 1922–6PubMedGoogle Scholar
  96. 96.
    Diamond T, McGuigan L, Barbagallo S, et al. Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women. Am J Med 1995; 98: 459–63PubMedGoogle Scholar
  97. 97.
    Worth H, Stammen D, Keck E. Therapy of steroid-induced bone loss in adult asthmatics with calcium, vitamin D, and diphosphonate. Am J Respir Crit Care Med 1994; 150: 394–7PubMedGoogle Scholar
  98. 98.
    Gallacher SJ, Fenner JAK, Anderson K, et al. Intravenous Pamidronate in the treatment of osteoporosis associated with corticosteroid dependent lung disease: an open pilot study. Thorax 1992; 47: 932–6PubMedGoogle Scholar
  99. 99.
    Rolla G, Bucca C, Brussino L. Biphosphonate-induced bronchoconstriction in aspirin-sensitive asthma. Lancet 1994; 343: 426–7PubMedGoogle Scholar
  100. 100.
    Gallacher SJ, Anderson K, Speekenbrink T, et al. A comparison of the effect of etidronate, Pamidronate, clodronate and calcium in patients with corticosteroid-dependent lung disease [abstract]. Calcif Tissue Int 1995; 56: 447Google Scholar
  101. 101.
    Greenwald M, Brandli D, Spector S, et al. Corticosteroid-induced osteoporosis: effects of a treatment with slow-release sodium fluoride. Osteoporos Int 1992; 2: 303–4PubMedGoogle Scholar
  102. 102.
    Lukert BP, Johnson BE, Robinson RG. Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone loss. J Bone Miner Res 1992; 7: 1063–9PubMedGoogle Scholar
  103. 103.
    Adami S, Fossaluzza V, Rossini M, et al. The prevention of corticosteroid-induced osteoporosis with nandrolone decanoate. Bone Miner 1991; 15: 72–81Google Scholar
  104. 104.
    Grecu EO, Weinshelbaum A, Simmons R. Effective therapy of glucocorticoid-induced osteoporosis with medroxyprogesterone acetate. Calcif Tissue Int 1990; 46: 294–9PubMedGoogle Scholar
  105. 105.
    Cundy T, Evans M, Roberts H, et al. Reduced bone density in women using depo-medroxyprogesterone acetate for contraception. BMJ 1991; 303: 13–16PubMedGoogle Scholar
  106. 106.
    Gennari C, Imbimbo B, Montagnani M, et al. Effects of prednisolone and deflazacort on mineral metabolism and parathyroid hormone activity in humans. Calcif Tissue Int 1985; 37: 592–3PubMedGoogle Scholar
  107. 107.
    Gray RES, Doherty SM, Galloway J, et al. A double-blind study of deflazacort and prednisone in patients with chronic inflammatory disorders. Arthritis Rheum 1991; 34: 287–95PubMedGoogle Scholar
  108. 108.
    Messina OD, Barreira JC, Zanchetta JR, et al. Effects of low doses of deflazacort vs prednisone on bone mineral content in premenopausal rheumatoid arthritis. J Rheumatol 1992; 19: 1520–6PubMedGoogle Scholar
  109. 109.
    Olgaard K, Storm T, Wowern NV, et al. Glucocorticoid-induced osteoporosis in the lumbar spine, forearm, and mandible of nephrotic patients: a double-blind study on the high-dose long term effect of prednisone versus deflazacort. Br J Rheumatol 1993; 32 Suppl. 2: 15–23Google Scholar
  110. 110.
    Loftus J, Allen R, Hesp R, et al. Randomized, double-blind trial of deflazacort versus prednisone in juvenile chronic (or rheumatoid) arthritis: a relatively bone-sparing effect of deflazacort. Pediatrics 1991; 88: 428–36PubMedGoogle Scholar
  111. 111.
    Gennari C, Imbimbo B. Effects of prednisone and deflazacort on vertebral bone mass. Calcif Tissue Int 1984; 36: 245–52PubMedGoogle Scholar
  112. 112.
    Avioli LV. Potency ratio: a brief synopsis. Br J Rheumatol 1993; 32 Suppl. 2: 24–6PubMedGoogle Scholar
  113. 113.
    Bruno A, Cavallo-Perin P, Cassader M, et al. Deflazacort versus prednisone: effects on blood glucose control in insulin-treated diabetics. Arch Intern Med 1987; 147: 679–80PubMedGoogle Scholar
  114. 114.
    Whedon GD. Disuse osteoporosis: physiological aspects. Calcif Tissue Int 1984; 36: 146–50Google Scholar
  115. 115.
    Praet JP, Peretz A, Rozenberg S, et al. Risk for osteoporosis in men with chronic bronchitis. Osteoporos Int 1992; 2: 257–61PubMedGoogle Scholar
  116. 116.
    Kelepouris N, Harper KD, Gannon F, et al. Severe osteoporosis in men. Ann Intern Med 1995; 123: 452–60PubMedGoogle Scholar
  117. 117.
    Jackson JA, Kleerekoper M, Parfitt AM, et al. Bone histomorphometry in hypogonadal and eugonadal men with spinal osteoporosis. J Clin Endocrinol Metab 1987; 65: 53–8PubMedGoogle Scholar
  118. 118.
    Croucher PI, Vedi S, Motley RJ, et al. Reduced bone formation in patients with osteoporosis associated with inflammatory bowel disease. Osteoporos Int 1993; 3: 236–41PubMedGoogle Scholar
  119. 119.
    Julian BA, Laskow DA, Dubovsky J, et al. Rapid loss of vertebral mineral density after renal transplantation. N Engl J Med 1991; 325: 544–50PubMedGoogle Scholar
  120. 120.
    Lee AH, Mull RL, Keenan GF, et al. Osteoporosis and bone morbidity in cardiac transplant recipients. Am J Med 1994; 96: 35–41PubMedGoogle Scholar
  121. 121.
    Meys E, Fontanges E, Fourcade N, et al. Bone loss after orthotopic liver transplantation. Am J Med 1994; 97: 445–50PubMedGoogle Scholar
  122. 122.
    Hamilos DL. Glucocorticoid osteoporosis: a need for greater awareness and action. J Asthma 1994; 31: 1–6PubMedGoogle Scholar
  123. 123.
    Clements D, Compston JE, Evans WD, et al. Hormone replacement therapy prevents bone loss in patients with inflammatory bowel disease. Gut 1993; 34: 1543–6PubMedGoogle Scholar
  124. 124.
    Adami S, Ortolani S, Wasnich R. Evaluation of therapeutic efficacy in osteoporosis. Osteoporos Int 1995; 5: 75–8PubMedGoogle Scholar
  125. 125.
    Luengo M, Picado C, Del Río L, et al. Vertebral fractures in steroid dependent asthma and involutional osteoporosis: a comparative study. Thorax 1991; 46: 803–6PubMedGoogle Scholar

Copyright information

© Adis International Limited 1996

Authors and Affiliations

  • César Picado
    • 1
  • Maite Luengo
    • 1
  1. 1.Servei de Pneumologia i Allergia Respiratoria, Departament de MedicinaHospital Clinic i Universitari, Facultat de MedicinaBarcelonaSpain

Personalised recommendations